Who are EKB-569's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Rybrevant, NERATINIB, REGORAFENIB, Inlyta, PONATINIB HYDROCHLORIDE, PAZOPANIB.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ekb-569.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

EKB-569 — Competitive Intelligence Brief

EKB-569 (EKB-569) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: tyrosine kinase inhibitor. Area: Oncology.

phase 2 tyrosine kinase inhibitor EGFR Oncology Small molecule Live · refreshed every 30 min

Target snapshot

EKB-569 (EKB-569) — Wyeth is now a wholly owned subsidiary of Pfizer. EKB-569 is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
EKB-569 TARGET	EKB-569	Wyeth is now a wholly owned subsidiary of Pfizer	phase 2	tyrosine kinase inhibitor	EGFR
Rybrevant	AMIVANTAMAB	Johnson & Johnson	marketed		EGFR, MET	2021-01-01
NERATINIB	NERATINIB		marketed		EGFR, HER2, HER4	2017-01-01
REGORAFENIB	REGORAFENIB		marketed		RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2, TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAF V600E, SAPK2, PTK5, Abl, CSF1R	2012-01-01
Inlyta	Axitinib	Pfizer	marketed	Receptor tyrosine kinase inhibitor	Vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, VEGFR-3	2012-01-01
PONATINIB HYDROCHLORIDE	PONATINIB HYDROCHLORIDE		marketed		ABL, T315I mutant ABL, VEGFR, PDGFR, FGFR, EPH receptors, SRC family, KIT, RET, TIE2, FLT3	2012-01-01
PAZOPANIB	PAZOPANIB		marketed	Kinase Inhibitor [EPC]	VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-ɑ, PDGFR-β, FGFR-1, FGFR-3, Kit, Itk, Lck, c-Fms	2009-01-01

Recent regulatory actions (last 90 days)

2026-02-13 — Rybrevant · FDA · approved · US · Johnson & Johnson

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (tyrosine kinase inhibitor class)

Centre Leon Berard · 2 drugs in this class
Akeso · 1 drug in this class
Astex Pharmaceuticals, Inc. · 1 drug in this class
Chengdu Zenitar Biomedical Technology Co., Ltd · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
Jiangsu ShengDiYa Medicine Co., Ltd. · 1 drug in this class
Nanjing Leads Biolabs Co.,Ltd · 1 drug in this class
Ocular Therapeutix, Inc. · 1 drug in this class
Peking University Cancer Hospital & Institute · 1 drug in this class
Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). EKB-569 — Competitive Intelligence Brief. https://druglandscape.com/ci/ekb-569. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab